about
Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligandsCrystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug designNew 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle functionSynthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activitySynthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonistsNew 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expressionResveratrol and Its Metabolites Bind to PPARsStructural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophyOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesInsights into the complex formed by matrix metalloproteinase-2 and alloxan inhibitors: molecular dynamics simulations and free energy calculationsBetulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis.Identification of novel matrix metalloproteinase inhibitors by screening of phenol fragments library.Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligandsOpen tubular columns containing the immobilized ligand binding domain of peroxisome proliferator-activated receptors α and γ for dual agonists characterization by frontal affinity chromatography with mass spectrometry detection.LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.Single-Nucleotide Polymorphism of PPARγ, a Protein at the Crossroads of Physiological and Pathological Processes.Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption.Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity.Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis.Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.Molecular determinants for the activating/blocking actions of the 2H-1,4-benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels.Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension?Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids.Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.Structural nucleotide analogs are potent activators/inhibitors of pancreatic β cell KATP channels: an emerging mechanism supporting their use as antidiabetic drugs.Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors.Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer's DiseaseStructural development studies of PPARs ligands based on tyrosine scaffoldA Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic DisordersNovel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesisAn update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligandsNew Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) ActivationNovel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic SyndromeBone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy
P50
Q27644330-3855B303-4BAD-464B-AB83-22FAE288C1A2Q27653049-293CB182-D860-4400-8F02-D6F359069BC4Q27657537-B817205C-6155-4B32-BBC8-E194BA44540FQ27675558-3CB28D0D-0EC5-456E-8200-06CCAD31561FQ27677316-1DD647D7-F79A-4C66-BB8D-D5178AB73476Q27683494-DC5C02C0-214C-4C5E-B005-9417EBD80AD1Q27683643-B845E882-8DC3-4327-AADC-C6CC97A55059Q27694510-6FEC622A-1D25-495C-BD1C-513AAE2F9D87Q27697692-E2B56F23-2B21-4A07-95A6-E4C3CA152123Q28477370-C2CD5130-E00C-44D6-BA55-2A36AA852DBFQ33916179-6A15B988-5E4D-48BB-889B-7C5BCF6C3447Q33939916-6F417742-0A74-46D7-B067-D8A1EB5753BBQ36446249-AA526282-5AE5-4958-83E8-0E9034AED211Q36744783-D05248FF-D9E8-49BA-A5F9-E295375CE1FBQ37622614-F0600448-8094-472D-80F3-A5025C2C4253Q37690874-D74D854C-EF72-42C7-96B4-CAB74EB4E56FQ38929844-8AEDA2CF-951A-4ADB-975F-ADB60D93B666Q39091093-1D80DE99-7CB3-49A7-A63A-569CA8A6ACC7Q39249230-FFDB7955-872D-47B5-8579-AEE40DF94C3BQ39516147-AFC96B8C-38E6-436A-92D1-95D7841B190CQ39932505-BA318E40-68FD-45AE-8DE7-BA6E30635C35Q40159652-8EE9908C-5C8D-44E2-8143-58E4C22A6104Q40384102-25EE239A-7EE9-45F1-8AC6-A4AF5CDE437AQ42167984-86FEE939-AF8E-4DE7-A9DF-F9C7FC1E978EQ43624351-D8E2B29C-3E29-4AE1-8FCE-0CFA731460CDQ46651589-CF5B2B5B-7F37-437A-914B-938ECCCA5F49Q47111177-B7772D87-8C59-4433-84F6-D75F7794024BQ47574341-E6A57099-0D4D-4F98-AF25-7AC723A80D3DQ47742715-6B257D38-453F-42EB-A214-94862FDFDF3EQ51243956-D97B27FB-8976-4A88-8F67-75CDD38A6EC2Q51366317-39474A95-F50C-4205-800B-FA76CDBBCB02Q51830769-472BC436-BCEF-4DFB-A0DF-DD2514FB35CAQ57166995-D150F843-0DE7-4553-AF3C-42DAE8D21DB7Q86152430-077C4AD6-7636-4264-B1D9-66A9DA9A11CCQ90295936-E4DFA61F-9327-4E0F-A184-8E523D3A2B68Q91451506-DC1F25BE-85C5-4554-B5BA-E3C413ED3C3CQ92190771-A29A4045-0B1E-41C1-9853-E1E91656F269Q92589154-CDA1F748-947A-4DD0-AEA8-0432504AC68EQ93166722-0FEEF6ED-3A3B-43F6-A2DE-7FBB45F076FFQ96125401-46C87CE2-777E-4A26-BDC7-A34EA0BAAF5A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Laghezza
@ast
Antonio Laghezza
@en
Antonio Laghezza
@es
Antonio Laghezza
@nl
type
label
Antonio Laghezza
@ast
Antonio Laghezza
@en
Antonio Laghezza
@es
Antonio Laghezza
@nl
prefLabel
Antonio Laghezza
@ast
Antonio Laghezza
@en
Antonio Laghezza
@es
Antonio Laghezza
@nl
P106
P21
P31
P496
0000-0001-6221-6155